Copper Histidinate Treatment for Menkes Disease

Sentynl Therapeutics, Inc.35 个研究点分布在 1 个国家开始时间: 2019年8月30日最近更新: 2026年3月2日

适应症

试验速览

This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.

•The subject must have been treated in protocol 09-CH-0059 or must be a newly diagnosed Menkes disease patient in the US.
•Parent or legal guardian is willing and able to sign and date an informed consent form.
•Male or female, aged 0 to <6 years of age.
•Diagnosis of Menkes disease: A confirmed gene mutation in ATP7A is not required; however, the test must be at least pending prior to initiating therapy. For those patients whose molecular ATP7A gene mutation confirmation is pending, they should have serum copper <75 mcg/dL. If the mutation is subsequently not confirmed, the patient should discontinue treatment.
•Ability to adhere to the prescribed subcutaneous copper histidinate injection regimen.
•Willingness to adhere to all recommended visits and procedures.
•Resident of the US.

•Diagnosis of Wilson disease.
•Any disease or condition that, in the opinion of the Investigator, has a high probability of precluding the subject from completing the study or where the subject cannot or will not appropriately comply with study requirements.
•Receipt of concomitant medication or device not approved for any use (i.e. experimental) by FDA within 30 days prior to screening for this study, except for participation in protocol 09-CH-
•Patient/caregiver cannot or will not appropriately comply with protocol recommendations (e.g., site visits, renal monitoring).
•Currently receiving any concomitant copper-containing medications.

发起方

申办方类型

Industry

责任方

Sponsor

Loading locations...